<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0601256517
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1993
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        MIACIN 500MG-2ML AMP
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        AMIKACIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        250
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Parenteral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        2
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        6
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Ampoule
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        125.4
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Hikma Farmaceutica" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Hikma Farmaceutica
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 441]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)	
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01GB06
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Miacin is one of a group of antibiotic medicines called &lsquo;aminoglycosides&rsquo;.</p><p>Miacin is used in the treatment of serious infections caused by bacteria sensitive to amikacin.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use Miacin</strong></p><ul><li>If you have shown signs of hypersensitivity (severe allergy) to amikacin, or any of the other ingredients listed in section 6, in the past</li><li>If you suffer from a disorder called myasthenia gravis (severe weakness of certain muscles of the body)</li></ul><p>Tell your doctor if any of the above applies to you before this medicine is used.</p><p><strong>Warnings and precautions</strong><br />Talk to your doctor before using Miacin:</p><ul><li>If you have kidney problems</li><li>If you have hearing difficulties or tinnitus (ringing or buzzing in the ears)</li><li>If you have shown signs of allergy to any of the antibiotics related to amikacin (aminoglycosides) in the past</li><li>If you or your family members have a mitochondrial mutation disease (condition caused by variants in the genome of mitochondria, the parts of your cells which help make energy) or loss of hearing due to antibiotic medicines; certain mitochondrial mutations may increase your risk of hearing loss with this product</li><li>If you have a known allergy to sulphites</li></ul><p>Tell your doctor if any of the above applies to you before this medicine is used.</p><p><strong>Children</strong><br />Miacin should be used with caution in premature and neonatal infants.</p><p><strong>Other medicines and Miacin</strong><br />Tell your doctor if you are taking, have recently taken or might take/use any other medicines.</p><p>Special care is needed if you are taking/using other medicines, as some could interact with amikacin for example:</p><ul><li>Diuretics (water tablets) such as furosemide and ethacrynic acid</li><li>Other antibiotics that can affect your kidneys, hearing or balance</li><li>Anaesthetics or muscle-relaxing drugs</li><li>Indomethacin (an anti-inflammatory medicine)</li><li>Other antibiotics called beta-lactamases such as penicillins or cephalosporins</li><li>Bisphosphonates; drugs used to treat loss of bone mass</li><li>Vitamin B1 (thiamine)</li><li>Platinum compounds used in chemotherapy such as cisplatin</li></ul><p><strong>Pregnancy and breast feeding</strong><br />If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine. Your doctor will only use this medicine if the expected benefits outweigh any potential risk to your baby.</p><p><strong>Driving and using machines</strong><br />Do not drive or use machines if you experience any side effect (e.g. dizziness) which may lessen your ability to do so.</p><p><strong>Miacin contains sodium and sodium metabisulphite</strong><br />Miacin contains sodium. Each 2 ml of Miacin 500 mg/2 ml Solution for Injection/Infusion contains 0.656<br />mmol (15.088 mg) sodium. This medicine contains less than 1 mmol sodium (23 mg) per 2 ml, that is to say essentially &lsquo;sodium-free&rsquo;.</p><p>Miacin contains sodium metabisulphite. Each 2 ml of Miacin 500 mg/2 ml Solution for Injection/Infusion<br />contains 13.181 mg sodium metabisulphite. &nbsp;May rarely cause severe hypersensitivity reactions and bronchospasm.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>This medicine is usually injected into a muscle. It may also be given into a vein, either as an injection or (following dilution) as an infusion (drip).</p><p>Miacin can also be given into the peritoneum (abdominal cavity) during surgery, and can be used to wash out abscess cavities, the lung cavity and brain cavities.</p><p>Your doctor will ensure you are well hydrated before and during treatment.</p><p><strong>Dose</strong><br />Your doctor will work out the correct dose of amikacin for you and how often it must be given. This may require blood tests before treatment.</p><p>The dose will depend upon your age, the infection you have, how well your kidneys are working, if you have poor hearing and any other medicines you may be taking.</p><p>It will usually be given to you two or three times a day, for up to 10 days.</p><p><em>Adults and children over 12 years:</em><br />The usual dose is 15 mg per kg per day which is administered as a single dose or divided into two equal doses of 7.5 mg per kg administered every 12 hours. The total dose should not exceed 1.5 g. When treatment is given in to a vein it is usually administered over a 30 to 60 minute period.</p><p><em>Children up to 12 years:</em><br />The usual dose is 15 &ndash; 20 mg per kg of body weight once a day or divided into two equal doses of 7.5 mg per kg which is administered every 12 hours.</p><p><em>Neonates:</em><br />The initial dose is 10 mg per kg of body weight followed by 7.5 mg per kg every 12 hours.</p><p><em>Premature infants:</em><br />The recommended dosing in premature babies is 7.5 mg per kg every 12 hours.</p><p>During treatment you may undergo blood tests and be asked to provide urine samples. You will possibly also have hearing tests before and during treatment to look for signs of side effects. Your doctor may change your dose depending upon the results of these tests.</p><p><strong>If you are given too much or too little Miacin</strong><br />This medicine will be given to you in a hospital, under the supervision of a doctor. It is unlikely that you will be given too much or too little, however, tell your doctor or nurse if you have any concerns.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p><strong><em>If any of the following happens, tell your doctor immediately as these are all serious. You may need urgent medical attention or hospitalisation.</em></strong><br /><strong>Rare side-effects may affect up to 1 in 1,000 people are listed below:</strong></p><ul><li>Ringing in your ears or loss of hearing</li><li>Decrease in the amount of urine you produce</li></ul><p><strong>Not known: frequency cannot be estimated from available data are listed below:</strong></p><ul><li>Severe allergic reaction - you may experience a sudden itchy rash (hives), swelling of the hands, feet, ankles, face, lips, mouth or throat (which may cause difficulty in swallowing or breathing), and you may feel you are going to faint</li><li>Paralysis</li><li>Deafness</li><li>Sudden loss of breathing</li><li>Severe kidney failure</li></ul><p>These are serious side effects. You may need urgent medical attention.</p><p><strong><em>If any of the following happens, tell your doctor as soon as possible:</em></strong><br /><strong>Uncommon side-effects may affect up to 1 in 100 people are listed below:</strong></p><ul><li>Skin rash</li><li>Nausea and vomiting</li><li>An excessive build up of bacteria or yeast which are resistant to amikacin</li></ul><p><strong>Rare side-effects may affect up to 1 in 1,000 people are listed below:</strong></p><ul><li>Dizziness or vertigo (spinning sensation)</li><li>Headache</li><li>Fever</li><li>Unusually low amount of red blood cells in the blood (anaemia) or excessive amounts of the white blood cells known as eosinophils in the blood (eosinophilia)</li><li>Low levels of magnesium in the blood</li><li>Abnormal tingling or &lsquo;pins and needles&rsquo; sensation</li><li>Muscle tremors</li><li>Joint pain</li><li>Low blood pressure</li><li>Itching or hives</li></ul><p>Amikacin may lead to changes in your kidney function. Your doctor may take blood and urine samples to monitor for changes such as increased levels of creatinine or nitrogen in the blood and protein or red/white blood cells in urine. Your doctor may also ask you to undergo hearing tests.</p><p>If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Store below 25&deg;C.</p><p>Store in the original package.</p><p>Unused portions of opened ampoules must not be stored for later use.</p><p>Prepared injections or infusions should be used immediately, however, if this is not possible they can be stored for up to 24 hours at room temperature.</p><p>Do not use this medicine after the expiry date which is stated on the package after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p><p>Do not use<strong> </strong>this medicine if you notice any visible signs of deterioration.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is amikacin sulphate.</p><p>Each 2 ml of Miacin 500 mg/2 ml Solution for Injection/Infusion contains 667.49 mg amikacin sulphate equivalent to 500 mg amikacin.</p><p>The other ingredients are sodium metabisulphite, trisodium citrate, sulfuric acid and/or sodium hydroxide and water for injection.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Miacin 500 mg/2 ml Solution for Injection/Infusion is a clear colourless to pale yellow solution in 2 ml amber glass ampoules with white one-point-cut (OPC).
 
Pack size: 6 Ampoules (2 ml).



            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder</strong></p><p>Jazeera Pharmaceutical Industries<br />Al-Kharj Road<br />P.O. Box 106229<br />Riyadh 11666, Saudi Arabia<br />Tel: + (966-11) 8107023, + (966-11) 2142472<br />Fax: + (966-11) 2078170<br />e-mail: SAPV@hikma.com</p><p><strong>Manufacturer</strong></p><p>Hikma Farmaceutica (Portugal), S.A.</p><p>Estrada do Rio Da M&oacute;,</p><p>n.&deg;8, 8A e 8B, Ferven&ccedil;a</p><p>2705-906 Terrugem</p><p>Sintra, Portugal</p><p>Tel: + (351-2) 19608410</p><p>Fax: + (351-2) 19615102</p><p><strong>Reporting of side effects</strong><br />If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects, you can also help provide more information on the safety of this medicine.</p><ul><li>Saudi Arabia</li></ul><p>The National Pharmacovigilance Centre (NPC)</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><ul><li>Other GCC States</li></ul><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 06/2023; version number SA2.0.


            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">ينتمي مياسين لمجموعة من المضادات الحيوية تُعرف باسم &rsquo;الأمينوجليكوزيدات&lsquo;.</p><p dir="RTL">يستخدم مياسين لعلاج حالات العدوى الخطيرة التي تسببها البكتيريا التي تعد حساسة للأميكاسين.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تستخدم مياسين</strong></p><ul dir="rtl"><li>إذا ظهرت عليك سابقاً علامات فرط التحسس (الحساسية الشديدة) لأميكاسين، أو لأي من المواد الأخرى المستخدمة في تركيبة هذا الدواء المدرجة في القسم 6.</li><li>إذا كنت تعاني من اضطراب يسمى مرض الوهن العضلي الوبيل (ضعف شديد في بعض عضلات الجسم).</li></ul><p>أخبر طبيبك إذا كان أي مما سبق ينطبق عليك وذلك قبل استخدام هذا الدواء.<strong>&nbsp;</strong></p><p dir="RTL"><strong>الاحتياطات والتحذيرات</strong><br />تحدث مع طبيبك قبل استخدام مياسين:</p><ul dir="rtl"><li>إذا كنت تعاني من مشاكل في الكلى</li><li>إذا كنت تعاني من صعوبة في السمع أو طنين في الأذن (سماع صوت رنين أو أزيز في الأذن)</li><li>إذا ظهرت عليك سابقاً علامات تحسس لأي من المضادات الحيوية ذات الصلة بالأميكاسين (مجموعة الأمينوجليكوزيدات)</li><li>إذا كنت أنت أو أحد أفراد أسرتك مصابًا بمرض طفرة الميتوكوندريا (حالة ناتجة عن متغيرات في جينوم الميتوكوندريا، وأجزاء الخلية التي تساعد في إنتاج الطاقة) أو فقدان السمع بسبب أدوية المضادات الحيوية؛ قد تؤدي بعض طفرات الميتوكوندريا إلى زيادة خطر الإصابة بفقدان السمع مع هذا المستحضر</li><li>إذا كنت تعاني من حساسية معينة للكبريتات</li></ul><p dir="RTL">أخبر طبيبك إذا كان أي مما سبق ينطبق عليك وذلك قبل استخدام هذا الدواء.</p><p dir="RTL"><strong>الأطفال</strong><br />يجب استخدام مياسين بحذر في الأطفال الخدج وحديثي الولادة.</p><p dir="RTL"><strong>الأدوية الأخرى ومياسين</strong><br />أخبر طبيبك إذا كنت تتناول، تناولت مؤخراً أو قد تتناول/تستخدم أي أدوية أخرى.<strong>&nbsp;</strong></p><p dir="RTL">يجب توخي الحذر إذا كنت تتناول/ تستخدم أدوية أخرى لأن بعض الأدوية قد تتداخل مع الأميكاسين مثل:</p><ul dir="rtl"><li>مدرات البول (أقراص الماء) مثل الفوروسيميد وحمض الإيثاكرِينِيك</li><li>المضادات الحيوية الأخرى التي قد تؤثر على كليتيك، سمعك أو توازنك</li><li>الأدوية المخدِرة أو المرخية للعضلات</li><li>الإندوميثاسين (دواء مضاد للالتهاب)</li><li>المضادات الحيوية من مجموعة بيتا لاكتاماز مثل البنسلين أو السيفالوسبورين</li><li>البسفُسفونات؛ أدوية تُستخدم لعلاج ترقق العظام</li><li>فيتامين B1 (ثيامين)</li><li>مركبات البلاتين التي تُستخدم في العلاج الكيميائي مثل السِيسبلاتين</li></ul><p dir="RTL"><strong>الحمل والرضاعة</strong><br />استشيري طبيبك أو الصيدلي إذا كنت حاملاً أو مرضعاً، تعتقدين بأنك حامل أو تخططين لذلك قبل اخذ هذا الدواء. قد يطلب منك طبيبك استخدام هذا الدواء إذا كانت الفائدة المتوقعة تفوق أية مخاطر محتملة قد تؤثر على طفلك.</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong><br />لا تقم بالقيادة أو استخدام الآلات إذا كنت تعاني من أية آثار جانبية (مثل الدوخة) والتي قد تؤثر على قدرتك على القيام بهذه الأنشطة.</p><p dir="RTL"><strong>يحتوي مياسين على الصوديوم ومیتابیسلفیت الصودیوم</strong><br />يحتوي مياسين على الصوديوم. يحتوي كل 2 مللتر من مياسين 500 ملغم/2 مللتر محلول للحقن/للتسريب على 0,656 ملمول (15,088 ملغم) صوديوم. يحتوي هذا الدواء على أقل من 1 ملمول صوديوم (23 ملغم) لكل 2 مللتر، بمعنى أنه &rsquo;خالٍ من الصوديوم&lsquo; بشكل أساسي.</p><p dir="RTL">يحتوي مياسين على ميتابيسلفيت الصوديوم. يحتوي كل 2 مللتر من مياسين 500 ملغم/2 مللتر محلول للحقن/للتسريب على 13,181 ملغم میتابیسلفیت الصودیوم. هذا قد يتسبب بشكل نادر بحدوث حساسية مفرطة وتشنجات في القصبة الهوائية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُحقن هذا الدواء عادة في العضل. كما يمكن إعطائه أيضاً في الوريد، إما بالحقن أو (بعد التخفيف) من خلال التسريب (التقطير).</p><p dir="RTL">ويمكن أيضاً إعطاء مياسين في الصفاق (تجويف البطن) أثناء الجراحة، ويمكن استخدامه لغسل التجاويف التي تحتوي على خراج، تجويف الرئة وتجاويف الدماغ.</p><p dir="RTL">سيتأكد طبيبك من تناولك ما يكفي من السوائل قبل العلاج وخلاله.</p><p dir="RTL"><strong>الجرعة</strong><br />سيحدد طبيبك مقدار وعدد الجرعات المناسبة لك من أميكاسين. قد يتطلب هذا إجراء بعض فحوصات الدم قبل العلاج.</p><p dir="RTL">ستعتمد الجرعة على عمرك، نوع العدوى المصاب بها، مدى كفاءة كليتيك، ما إذا كنت تعاني من ضعف في السمع ووجود أي أدوية أخرى قد تكون تأخذها.</p><p dir="RTL">سيُعطى لك الدواء عادة مرتين او ثلاث مرات يوميًا ولمدة قد تصل إلى 10 أيام.</p><p dir="RTL"><em>البالغ</em><em>ون والأطفال الذين تجاوزوا الـ 12 عامًا:</em><br />الجرعة المعتادة هي 15 ملغم لكل كغم يوميًا تُعطى في جرعة واحدة أو تُقسّم إلى جرعتين متساويتين تبلغ كل منهما 7,5 ملغم لكل كغم كل 12 ساعة. يجب ألا تتجاوز الجرعة الكلية 1,5 غم. عند إعطاء العلاج في الوريد فإنه يُعطى عادة على مدى 30 إلى 60 دقيقة.</p><p dir="RTL"><em>الأطفال حتى الـ 12 عامًا:</em><br />الجرعة المعتادة هي 15-20 ملغم لكل كغم من وزن الجسم يوميًا تُعطى في جرعة واحدة أو تُقسّم إلى جرعتين متساويتين تبلغ كل منهما 7,5 ملغم لكل كغم كل 12 ساعة.</p><p dir="RTL"><em>حديثو الولادة:</em><br />الجرعة الأولية هي 10 ملغم لكل كغم من وزن الجسم متبوعة بجرعة مقدارها 7,5 ملغم لكل كغم كل 12 ساعة.</p><p dir="RTL"><em>الأطفال الخدج:</em><br />الجرعة الموصى بها للأطفال الخدج هي 7,5 ملغم لكل كغم كل 12 ساعة.</p><p dir="RTL">قد تُجرى لك فحوصات للدم أثناء العلاج وقد يُطلب منك تقديم عينات بول. كما قد يُطلب منك إجراء فحص للسمع قبل العلاج وأثنائه لاكتشاف أي علامات لحدوث آثار جانبية. ووفقًا لنتائج هذه الفحوصات فقد يغير طبيبك الجرعة التي تتناولها.</p><p dir="RTL"><strong>إذا تم إعطاؤك جرعة </strong><strong>أكثر من اللازم<strong> </strong>أو جرعة قليلة من مياسين</strong><br />سيُعطى هذا الدواء لك في المستشفى تحت إشراف طبيب. من غير المحتمل أن تُعطى جرعة أكبر أو أقل من اللازم، مع ذلك، أخبر طبيبك أو الممرض إذا راودتك أية مخاوف.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية قد يسبب هذا الدواء آثاراً جانبيةً، إلا أنها لا تحدث لدى جميع مستخدمي هذا الدواء.</p><p dir="RTL"><strong><em>أخبر </em></strong><strong><em>طبيبك فوراً، إذا ظهرت عليك أي من الآثار التالية حيث تعد جميع هذه الآثار خطيرة. قد تحتاج إلى رعاية طبية عاجلة أو علاج طارئ في المستشفى.</em></strong><br /><strong>الآثار الجانبية النادرة التي قد تؤثر في ما يصل إلى شخص واحد من كل</strong><strong> 1000 شخص مدرجة أدناه:</strong></p><ul dir="rtl"><li>طنين في أذنك او فقدان السمع</li><li>انخفاض مقدار البول الذي تخرجه</li></ul><p dir="RTL"><strong>الآثار الجانبية </strong><strong>غير المعروفة: </strong><strong>لا يمكن تقدير تكرارها من البيانات المتاحة مدرجة أدناه:</strong></p><ul dir="rtl"><li>رد فعل تحسسي شديد - قد تتعرض لطفح جلدي مفاجئ مصحوب بحكة (شرى)، تورم في اليدين، القدمين، الكاحلين، الوجه، الشفتين، الفم أو الحلق (مما قد يسبب صعوبة في البلع أو التنفس)، وقد تشعر أنك على وشك الإغماء.</li><li>شلل</li><li>صمم</li><li>فقدان القدرة على التنفس فجأة</li><li>فشل كلوي شديد</li></ul><p>هذه الآثار الجانبية خطيرة، وقد تعني حاجتك إلى رعاية طبية عاجلة.</p><p><strong><em>أخبر طبيبك على الفور إذا حدثت لك أي من ما يلي:</em></strong><br /><strong>الآثار الجانبية غير الشائعة التي قد تؤثر في ما يصل إلى </strong><strong>شخص واحد من كل 100 شخص مدرجة أدناه:</strong></p><ul dir="rtl"><li>الطفح الجلدي</li><li>الغثيان والقيئ</li><li>تراكم كبير للبكتيريا أو الفطريات المقاومة للأميكاسين</li></ul><p><strong>الآثار الجانبية النادرة التي قد تؤثر في ما يصل إلى </strong><strong>شخص واحد من كل 1000 شخص مدرجة أدناه:</strong></p><ul dir="rtl"><li>الدوخة أو الدوار (الشعور بالدوران)</li><li>الصداع</li><li>الحمى</li><li>انخفاض عدد كريات الدم الحمراء إلى مستوى أقل من المعتاد (فقر الدم) أو ارتفاع عدد كريات الدم البيضاء التي تُعرف باسم يوزينات الدم (فرط اليوزينيات)</li><li>انخفاض مستوى المغنسيوم في الدم</li><li>وخز غير طبيعي أو شعور بوخز مثل &rsquo;الدبابيس أو الإبر&lsquo;</li><li>رعاش خفيف في العضلات</li><li>ألم في المفاصل</li><li>انخفاض ضغط الدم</li><li>حكة أو شرى</li></ul><p>قد يؤدي الأميكاسين إلى تغير في وظائف كليتيك. قد يطلب طبيبك عينات دم وبول لمتابعة ظهور أي من هذه التغيرات مثل ارتفاع مستوى الكرياتينين أو النتروجين في الدم أو وجود بروتين أو خلايا دم حمراء/بيضاء في البول. قد يطلب منك طبيبك أيضاً إجراء فحوصات للسمع.</p><p>يرجى إخبار طبيبك في حال أصبحت أي من الآثار الجانبية خطيرة، أو ملاحظتك لأي آثار جانبية غير مذكورة في هذه النشرة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيداً عن مرأى ومتناول الأطفال.</p><p dir="RTL">يحفظ عند درجة حرارة أقل من 30˚ مئوية.</p><p dir="RTL">يحفظ داخل العبوة الأصلية.</p><p dir="RTL">يجب عدم تخزين أي كميات متبقية من الأمبولات المفتوحة لاستخدامها لاحقًا.</p><p dir="RTL">يجب استخدام أي محاليل تم تحضيرها للحقن أو التسريب فورًا، ولكن، في حال تعذر ذلك، يمكن حفظها لمدة تصل إلى 24 ساعة عند درجة حرارة الغرفة.</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على العبوة الخارجية بعد &quot;EXP&quot;. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">لا تستخدم هذا الدواء إذا لاحظت أي علامات تلف واضحة عليه.</p><p dir="RTL">لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. هذه الإجراءات ستساعد في الحفاظ على سلامة البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هي سلفات الأميكاسين.</p><p dir="RTL">يحتوي كل 2 مللتر من مياسين 500 ملغم/2 مللتر محلول للحقن/للتسريب على 667,49 ملغم سلفات الأميكاسين تكافئ 500 ملغم أميكاسين.</p><p dir="RTL">المواد الأخرى المستخدمة في التركيبة التصنيعية هي ميتابيسلفايت الصوديوم، سیترات ثلاثي الصوديوم، حمض السلفوريك و/أو هيدروكسيد الصوديوم وماء معد للحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مياسين 500 ملغم/2 مللتر<strong> </strong>محلول للحقن/للتسريب هو محلول صافٍ عديم اللون إلى أصفر باهت في أمبولات زجاجية كهرمانية اللون بحجم 2 مللتر مع نقطة كسر واحدة بيضاء اللون.</p><p dir="RTL">&nbsp;</p><p dir="RTL">حجم العبوة: 6 أمبولات (2 مللتر).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك رخصة التسويق</strong></p><p dir="RTL">شركة الجزيرة للصناعات الدوائية<br />طريق الخرج<br />صندوق بريد 106229<br />الرياض 11666، المملكة العربية السعودية<br />هاتف: 8107023 (11-966) +، 2142472 (11-966) +<br />فاكس: 2078170 (11-966) +<br />البريد الإلكتروني: SAPV@hikma.com</p><p dir="RTL"><strong>الشركة المصنعة</strong></p><p dir="RTL">شركة أدوية الحكمة (البرتغال)، المساهمة العامة المحدودة<br />إسترادا دو ريو دا مو،</p><p dir="RTL">مبنى رقم <img alt="" width="60" height="11" src="data:image/png;base64,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" /> فارفانسا<br />906-2705 تيروجيم</p><p dir="RTL">سنترا، البرتغال<br />هاتف: 19608410 (2-351) +<br />فاكس: 19615102 (2-351) +</p><p dir="RTL"><strong>للإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">تحدث إلى الطبيب، الصيدلي، أو الممرض إذا عانيت من أية آثار جانبية. وذلك يشمل أي آثار جانبية لم يتم ذكرها في هذه النشرة. كما أنه يمكنك الإبلاغ عن هذه الآثار مباشرةً (انظر التفاصيل المذكورة أدناه). من خلال الإبلاغ عن الآثار الجانبية، يمكنك المساعدة بتوفير معلومات مهمة عن سلامة الدواء.</p><ul dir="rtl"><li>المملكة العربية السعودية</li></ul><p dir="RTL">المركز الوطني للتيقظ الدوائي</p><p dir="RTL">مركز الاتصال الموحد: 19999</p><p dir="RTL">البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">الموقع الإلكتروني: &nbsp;https://ade.sfda.gov.sa</p><ul dir="rtl"><li>دول الخليج العربي الأخرى</li></ul><p dir="RTL">الرجاء الاتصال بالجهات الوطنية في كل دولة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة بتاريخ 06/2023؛ رقم النسخة SA2.0.


        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Miacin 500 mg/2 ml Solution for Injection/Infusion
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each 2 ml contains 667.49 mg amikacin sulphate equivalent to 500 mg amikacin base.

Excipients with known effect: Sodium and sodium metabisulphite. 

For a full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for injection/infusion.

Clear colourless to pale yellow Solution.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Miacin is a semi-synthetic, aminoglycoside antibiotic which is active against a broad spectrum of Gram-negative organisms, including pseudomonas and some Gram-positive organisms.</p><p>Sensitive Gram-negative organisms include; Pseudomonas aeruginosa, Escherichia coli., indole-positive and indole-negative Proteus spp., Klebsiella, Enterobacter and Serratia spp., Minea-Herralae, Citrobacter freundii, Salmonella, Shigella, Acinetobacter and Providencia spp.</p><p>Many strains of these Gram-negative organisms resistant to gentamicin and tobramycin show sensitivity to amikacin in vitro.</p><p>The principal Gram-positive organism sensitive to amikacin is Staphylococcus aureus, including some methicillin-resistant strains. Amikacin has some activity against other Gram-positive organisms including certain strains of Streptococcus pyogenes, Enterococci and Diplococcus pneumoniae.</p><p>Amikacin is indicated in the short-term treatment of serious infections due to susceptible strains of Gram-negative bacteria, including Pseudomonas species. Although amikacin is not the drug of choice for infections due to staphylococci, at times it may be indicated for the treatment of known or suspected staphylococcal disease. These situations include: the initiation of therapy for severe infections when the organisms suspected are either Gram-negative or staphylococci, patients allergic to other antibiotics, and mixed staphylococcal/Gram-negative infections.</p><p>Therapy with amikacin may be instituted prior to obtaining the results of sensitivity testing. Surgical procedures should be performed where indicated.</p><p>Consideration should be given to official guidance on the appropriate use of antibacterial Agents.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Miacin may be given intramuscularly or intravenously.</p><p>Miacin should not be physically premixed with other drugs, but should be administered separately according to the recommended dose and route.</p><p>The patient&#39;s pre-treatment bodyweight should be obtained for calculation of correct dosage.</p><p>The status of renal function should be estimated by measurement of the serum creatinine concentration or calculation of the endogenous creatinine clearance rate. The blood urea nitrogen (BUN) is much less reliable for this purpose. Reassessment of renal function should be made periodically during therapy.</p><p>Whenever possible, amikacin concentrations in serum should be measured to assure adequate, but not excessive levels. It is desirable to measure both peak and trough serum concentrations intermittently during therapy. Peak concentrations (30-90 minutes after injection) above 35 mcg/ml and trough concentrations (just prior to the next dose) above 10 mcg/ml should be avoided. Dosage should be adjusted as indicated. In patients with normal renal function, once-daily dosing may be used; peak concentrations in these cases may exceed 35 mcg/ml.</p><p>For most infections the intramuscular route is preferred, but in life-threatening infections, or in patients in whom intramuscular injection is not feasible, the intravenous route, either slow bolus (2 to 3 minutes) or infusion (0.25% over 30 minutes) may be used.</p><p><strong>Intramuscular and intravenous administration</strong><br />At the recommended dosage level, uncomplicated infections due to sensitive organisms should respond to therapy within 24 to 48 hours.</p><p>If clinical response does not occur within three to five days, consideration should be given to alternative therapy.</p><p>If required, suitable diluents for intravenous use are: normal saline or 5% dextrose in water. Once the product has been diluted the solution must be used as soon as possible and NOT STORED.</p><p><em>Adults and Children over 12 years</em><br />The recommended intramuscular or intravenous dosage for adults and adolescents with normal renal function (creatinine clearance &ge;50 ml/min) is 15 mg/kg/day which may be administered as a single daily dose or divided into 2 equal doses i.e. 7.5 mg/kg q 12 h. The total daily dose should not exceed 1.5 g. In endocarditis and in febrile neutropenic patients, dosing should be twice daily, as there is not enough data to support once daily dosing.</p><p><em>Children 4 weeks to 12 years</em><br />The recommended intramuscular or intravenous (slow intravenous infusion) dose in children with normal renal function is 15-20 mg/kg/day which may be administered as 15-20 mg/kg, once a day; or as 7.5 mg/kg q 12 h. In endocarditis and in febrile neutropenic patients dosing should be twice daily, as there is not enough data to support once daily dosing.</p><p><em>Neonates</em><br />An initial loading dose of 10 mg/kg followed by 7.5 mg/kg q 12 h (see sections 4.4 and 5.2). &nbsp;</p><p><em>Premature Infants</em><br />The recommended dose in prematures is 7.5 mg/kg in every 12 hours (see sections 4.4 and 5.2).</p><p>The usual duration of treatment is 7 to 10 days. The total daily dose by all routes of administration should not exceed 15-20 mg/kg/day. In difficult and complicated infections where treatment beyond 10 days is considered, the use of amikacin sulphate injection should be re-evaluated and, if continued, renal, auditory, vestibular function should be monitored, as well as serum amikacin levels.</p><p>If definite clinical response does not occur within 3 to 5 days, therapy should be stopped and the antibiotic susceptibility pattern of the invading organism should be rechecked. Failure of the infection to respond may be due to resistance of the organism or to the presence of septic foci requiring surgical drainage.</p><p><strong>Intravenous administration</strong><br />The solution is administered to adults over a 30 to 60 minute period.</p><p><em>Specific recommendation for intravenous administration</em><br />In paediatric patients the amount of diluents used will depend on the amount of amikacin tolerated by the patient. The solution should normally be infused over a 30 to 60 minute period. Infants should receive a 1 to 2 hour infusion.</p><p><em>Elderly</em><br />Amikacin is excreted by the renal route, renal function should be assessed whenever possible and dosage adjusted as described under impaired renal function.</p><p><strong>Life-threatening infections and/or those caused by pseudomonas</strong><br />The adult dose may be increased to 500 mg every eight hours but should never exceed 1.5 g/day nor be administered for a period longer than 10 days. A maximum total adult dose of 15 g should not be exceeded.</p><p><strong>Urinary tract infections: (other than pseudomonas infections)</strong><br />7.5 mg/kg/day in two equally divided doses (equivalent to 250 mg b.i.d. in adults). As the activity of amikacin is enhanced by increasing the pH, a urinary alkalinising agent may be administered concurrently.</p><p><strong>Impaired renal function</strong><br />In patients with renal impairment reflected by creatinine clearance less than 50 ml/min, administration of the recommended total daily dose of amikacin in single daily doses is not desirable since these patients will have protracted exposure to high trough concentrations. See below for dosage adjustments in patients with impaired renal function.</p><p>For patients with impaired renal function receiving usual twice or three times daily dosing, whenever possible, serum amikacin concentrations should be monitored by appropriate assay procedures. Doses should be adjusted in patients with impaired renal function either by administering normal doses at prolonged intervals or by administering reduced doses at fixed intervals.</p><p>Both methods are based on the patient&#39;s creatinine clearance or serum creatinine values since these have been found to correlate with aminoglycoside half-lives in patients with diminished renal function. These dosage schedules must be used in conjunction with careful clinical and laboratory observations of the patient and should be modified as necessary, including modification when dialysis is being performed.</p><p><em>Normal Dose at Prolonged Intervals Between Dosing:</em> If the creatinine clearance rate is not available and the patient&#39;s condition is stable, a dosage interval in hours for the normal single dose (ie, that which would be given to patients with normal renal function on a twice daily schedule, 7.5 mg/kg) can be calculated by multiplying the patient&#39;s serum creatinine by nine; eg, if the serum creatinine concentration is 2mg/100 ml, the recommended single dose (7.5 mg/kg) should be administered every 18 hours.</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>Serum Creatinine Concentration</strong></p><p><strong>(mg/100 ml)</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Interval between amikacin doses of 7.5 mg/kg IM</strong></p><p><strong>(hours)</strong></p></td></tr><tr><td style="vertical-align:top"><p>1.5</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>13.5</p></td></tr><tr><td style="vertical-align:top"><p>2.0</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>18.0</p></td></tr><tr><td style="vertical-align:top"><p>2.5</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>22.5</p></td></tr><tr><td style="vertical-align:top"><p>3.0</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>27.0</p></td></tr><tr><td style="vertical-align:top"><p>3.5</p></td><td style="vertical-align:top"><p>X9=</p></td><td style="vertical-align:top"><p>31.5</p></td></tr><tr><td style="vertical-align:top"><p>4.0</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>36.0</p></td></tr><tr><td style="vertical-align:top"><p>4.5</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>40.5</p></td></tr><tr><td style="vertical-align:top"><p>5.0</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>45.0</p></td></tr><tr><td style="vertical-align:top"><p>5.5</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>49.5</p></td></tr><tr><td style="vertical-align:top"><p>6.0</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>54.0</p></td></tr></tbody></table><p>As renal function may alter appreciably during therapy, the serum creatinine should be checked frequently and the dosage regimen modified as necessary.</p><p><em>Reduced Dose at Fixed Time Intervals Between Dosing:</em> When renal function is impaired and it is desirable to administer amikacin sulfate injection at a fixed time interval, dose must be reduced. In these patients, serum amikacin concentrations should be measured to assure accurate administration and to avoid excessive serum concentrations. If serum assay determinations are not available, and patient&#39;s condition is stable, serum creatinine and creatinine clearance values are the most readily available indicators of the degree of renal impairment to use as a guide for dosage.</p><p>First initiate therapy by administering a normal dose, 7.5 mg/kg, as a loading dose. This dose is the same as the normally recommended dose which would be calculated for a patient with a normal renal function as described above.</p><p>To determine the size of maintenance doses administered every 12 hours, the loading dose should be reduced in proportion to the reduction in the patient&#39;s creatinine clearance rate:</p><p><img alt="" width="500" height="36" src="data:image/png;base64,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" /></p><p>(CrCl = creatinine clearance rate)</p><p>An alternate rough guide for determining reduced dosage at 12-hour intervals (for patients whose steady state serum creatinine values are known) is to divide the normally recommended dose by the patient&#39;s serum creatinine.</p><p>The above dosage schedules are not intended to be rigid recommendations, but are provided as guides to dosage when the measurement of amikacin serum levels is not feasible.</p><p><strong>Intraperitoneal use</strong><br />Following exploration for established peritonitis, or after peritoneal contamination due to faecal spill during surgery, amikacin may be used as an irrigant after recovery from anaesthesia in concentrations of 0.25% (2.5 mg/ml). The intraperitoneal use of amikacin is not recommended in young children.</p><p><strong>Other routes of administration</strong><br />Amikacin in concentrations 0.25% (2.5 mg/ml) may be used satisfactorily as an irrigating solution in abscess cavities, the pleural space, the peritoneum and the cerebral ventricles.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Miacin is contraindicated in patients with known allergy to amikacin or any component of the formulation.
A history of hypersensitivity or serious toxic reactions to aminoglycosides may contraindicate the use of any aminoglycoside because of the known cross sensitivities of patients to drugs in this class.
Aminoglycosides may impair neuromuscular transmission, and should not be given to patients with myasthenia gravis.
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Patients should be well hydrated during amikacin therapy.</p><p>Caution should be applied to patients with pre-existing renal insufficiency, pre-existing hearing or vestibular damage and diminished glomerular filtration. Patients treated with parenteral aminoglycosides should be under close clinical observation because of the potential ototoxicity and nephrotoxicity associated with their use. Safety for treatment periods which are longer than 14 days has not been established.</p><p>If therapy is expected to last seven days or more in patients with renal impairment, or 10 days in other patients, a pre-treatment audiogram should be obtained and repeated during therapy.</p><p><strong>Renal Toxicity</strong><br />Aminoglycosides are potentially nephrotoxic. Renal toxicity is independent of plasma obtained at the peak (C<sub>max)</sub>. The risk of nephrotoxicity is greater in patients with impaired renal function, and in those who receive higher doses, or in those whose therapy is prolonged.</p><p>Patients should be well hydrated during treatment and renal function should be assessed by the usual methods prior to starting therapy and daily during the course of treatment. A reduction of dosage is required if evidence of renal dysfunction occurs, such as presence of urinary casts, white or red cells, albuminuria, decreased creatinine clearance, decreased urine specific gravity, increased BUN, serum creatinine, or oliguria. If azotemia increases, or if a progressive decrease in urinary output occurs, treatment should be stopped.</p><p>Elderly patients may have reduced renal function which may not be evident in routine screening tests such as BUN or serum creatinine. A creatinine clearance determination may be more useful. Monitoring of renal function in elderly patients during treatment with aminoglycosides is particularly important.</p><p>Renal and eighth-cranial nerve function should be closely monitored especially in patients with known or suspected renal impairment at the onset of therapy, and also in those whose renal function is initially normal but who develop signs of renal dysfunction during therapy. Serum concentrations of amikacin should be monitored when feasible to assure adequate levels and to avoid potentially toxic levels. Urine should be examined for decreased specific gravity, increased excretion of proteins, and the presence of cells or casts. Blood urea nitrogen, serum creatinine, or creatinine clearance should be measured periodically. Serial audiograms should be obtained where feasible in patients old enough to be tested, particularly high risk patients. Evidence of ototoxicity (dizziness, vertigo, tinnitus, roaring in the ears, and hearing loss) or nephrotoxicity requires discontinuation of the drug or dosage adjustment.</p><p>Concurrent and/or sequential, oral, or topical use of other neurotoxic or nephrotoxic products, particularly bacitracin, cisplatin, amphotericin B, cephaloridine, paromomycin, viomycin, polymyxin B, colistin, vancomycin, or other aminoglycosides, should be avoided. Other factors that may increase risk of toxicity are advanced age and dehydration.</p><p>Patients suffering from pre-existing renal insufficiency should be assessed by the usual methods prior to therapy and periodically during therapy. Daily doses should be reduced and/or the interval between doses lengthened in accordance with serum creatinine concentrations to avoid accumulation of abnormally high blood levels and to minimise the risk of ototoxicity. Regular monitoring of serum drug concentration and of renal function is particularly important in elderly patients, who may have reduced renal function that may not be evident in the results of routine screening tests i.e. blood urea and serum creatinine.</p><p><strong>Neurotoxicity</strong><br />Neurotoxicity, manifested as vestibular and/or bilateral ototoxicity, can occur in patients treated with aminoglycosides. The risk of aminoglycoside-induced ototoxicity is greater in patients with impaired renal function, and in those who receive high doses, or in those whose therapy is prolonged over 5-7 days of treatment, even in healthy patients. High frequency deafness usually occurs first and can be detected only by audiometric testing. Vertigo may occur and may be evidence of vestibular injury. Other manifestations of neurotoxicity may include numbness, skin tingling, muscle twitching and convulsions.</p><p><strong>Ototoxicity</strong><br />The risk of ototoxicity due to aminoglycosides increases with the degree of exposure to either persistently high peak or high trough serum concentrations. Patients developing cochlear or vestibular damage may not have symptoms during therapy to warn them of developing eighth nerve toxicity, and total or partial irreversible bilateral deafness or disabling vertigo may occur after the drug has been discontinued. Aminoglycoside-induced ototoxicity is usually irreversible. Patients with mitochondrial DNA mutations, particularly the nucleotide 1555 A to G substitution in the 12S rRNA gene may be at higher risk for ototoxicity, even if the patient&#39;s aminoglycoside serum levels were within the recommended range. In case of family history of aminoglycoside-induced deafness or known mitochondrial DNA mutations in the 12S rRNA gene, alternative treatments other than aminoglycosides should be considered.</p><p><strong>Neuromuscular Toxicity</strong><br />Neuromuscular blockade and respiratory paralysis have been reported following parenteral injection, topical instillation (as in orthopaedic and abdominal irrigation or in local treatment of empyema), and following oral use of aminoglycosides. The possibility of respiratory paralysis should be considered if aminoglycosides are administered by any route, especially in patients receiving anaesthetics, neuromuscular blocking agents such as tubocurarine, succinylcholine, decamethonium, atracurium, rocuronium, vecuronium or in patients receiving massive transfusions of citrate-anticoagulated blood. If neuromuscular blockade occurs, calcium salts may reverse respiratory paralysis, but mechanical respiratory assistance may be necessary. Neuromuscular blockade and muscular paralysis have been demonstrated in laboratory animals given high doses of amikacin.</p><p>Amikacin must not be used in patients with myasthenia gravis. Aminoglycosides should be used with caution in patients with muscular disorders such as Parkinsonism since these drugs may aggravate muscle weakness because of their potential curare-like effect on the neuromuscular junction.</p><p><strong>Allergic reactions</strong><br />The use of amikacin in patients with a history of allergy to aminoglycosides or in patients who may have subclinical renal or eighth nerve damage induced by prior administration of nephrotoxic and/or ototoxic agents such as streptomycin, dihydrostreptomycin<strong>,</strong> gentamicin, tobramycin, kanamycin, neomycin, polymyxin B, colistin, cephaloridine or viomycin should be considered with caution, as toxicity may be additive. In these patients amikacin should be used only if, in the opinion of the physician, therapeutic advantages outweigh the potential risks.</p><p>Large doses of amikacin administered during surgery have been responsible for a transient myasthenic syndrome.</p><p>Miacin in ampoules contains sodium bisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is uncommon and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in non-asthmatic subjects.</p><p><strong>Paediatric use</strong><br />Aminoglycosides should be used with caution in premature and neonatal infants because of the renal immaturity of these patients and the resulting prolongation of serum half-life of these drugs.</p><p><strong>Other</strong><br />Aminoglycosides are quickly and almost totally absorbed when they are applied topically, except to the urinary bladder, in association with surgical procedures. Irreversible deafness, renal failure and death due to neuromuscular blockade have been reported following irrigation of both small and large surgical fields with an aminoglycoside preparation.</p><p>As with other antibiotics, the use of amikacin may result in overgrowth of non-susceptible organisms. If this occurs, appropriate therapy should be instituted.</p><p>Macular infarction sometimes leading to permanent loss of vision has been reported following intravitreous administration (injection into the eye) of amikacin.</p><p><strong>Excipients</strong><br />Miacin contains sodium. Each 2 ml contains 0.656 mmol (15.088 mg) sodium. This medicine contains less than 1 mmol sodium (23 mg) per 2 ml, that is to say essentially &lsquo;sodium-free&rsquo;.</p><p>Maicin contains sodium metabisulphite. Each 2 ml contains 13.181 sodium metabisulphite.&nbsp; May rarely cause severe hypersensitivity reactions and bronchospasm.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The concurrent or serial use of other neurotoxic, ototoxic or nephrotoxic agents, particularly bacitracin, cisplatin, amphotericin B, ciclosporin, tacrolimus, cephaloridine, paromomycin, viomycin, polymyxin B, colistin, vancomycin, or other aminoglycosides should be avoided either systemically or topically because of the potential for additive effects. Where this is not possible, monitor carefully.</p><p>Increased nephrotoxicity has been reported following concomitant parenteral administration of aminoglycoside antibiotics and cephalosporins. Concomitant cephalosporin use may spuriously elevate creatinine serum level determinations.</p><p>The concurrent use of amikacin sulfate injection with potent diuretics (ethacrynic acid or furosemide) should be avoided since diuretics by themselves may cause ototoxicity. In addition, when administered intravenously, diuretics may enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue.</p><p>In Vitro admixture of aminoglycosides with beta-lactam antibiotics (penicillins or cephalosporins) may result in significant mutual inactivation. A reduction in serum activity may also occur when an aminoglycoside or penicillin-type drug is administered <em>in vivo</em> by separate routes. Inactivation of the aminoglycoside is clinically significant only in patients with severely impaired renal function. Inactivation may continue in specimens of body fluids collected for assay, resulting in inaccurate aminoglycoside readings. Such specimens should be properly handled (assayed promptly, frozen, or treated with beta-lactamase).</p><p>There is an increased risk of hypocalcaemia when aminoglycosides are administered with bisphosphonates.</p><p>There is an increased risk of nephrotoxicity and possibly of ototoxicity when aminoglycosides are administered with platinum compounds.</p><p>Concomitantly administered thiamine (vitamin B1) may be destroyed by the reactive sodium bisulfite component of the amikacin sulfate formulation.</p><p>The intraperitoneal use of amikacin is not recommended in patients under the influence of anaesthetics or muscle-relaxing drugs (including ether, halothane, d-tubocurarine, succinylcholine and decamethonium) as neuromuscular blockade and consequent respiratory depression may occur.</p><p>Indomethacin may increase the plasma concentration of amikacin in neonates.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pregnancy</strong><br />The safety of amikacin in pregnancy has not yet been established. Amikacin should be administered to pregnant women and neonatal infants only when clearly needed and under medical supervision (see section 4.4).</p><p>There are limited data on use of aminoglycosides in pregnancy. Aminoglycosides can cause foetal harm. Aminoglycosides cross the placenta and there have been reports of total, irreversible, bilateral congenital deafness in children whose mothers received streptomycin during pregnancy. Adverse effects on the foetus or newborns have been reported in pregnant women treated with other aminoglycosides, therefore the potential for harm exists. If amikacin is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the foetus.</p><p><strong>Breast-feeding</strong><br />Amikacin is excreted in human milk. A decision should be made whether to discontinue breast-feeding or to discontinue therapy.</p><p><strong>Fertility</strong><br />In reproduction toxicity studies in mice and rats no effects on fertility or foetal toxicity were reported.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been performed. Due to the occurrence of some adverse reactions (see section 4.8) the ability to drive and use machines may be impaired.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This list is presented by system organ class, MedDRA preferred term, and frequency using the following frequency categories: very common (&ge;1/10), common (&ge;1/100, &lt; 1/10), uncommon (&ge;1/1000, &lt; 1/100), rare (&ge;1/10000, &lt; 1/1000), very rare (&lt;1/10000) and not known (cannot be estimated from the available data).</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td style="vertical-align:top"><p><strong>MedDRA Term</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Infections and Infestations</em></p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Superinfections or colonisation with resistant bacteria or yeast<sup>a</sup></p></td></tr><tr><td style="vertical-align:top"><p><em>Blood and lymphatic system disorders</em></p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Anaemia, eosinophilia</p></td></tr><tr><td style="vertical-align:top"><p><em>Immune system disorders</em></p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Anaphylactic response (anaphylactic reaction, anaphylactic shock and anaphylactoid reaction), hypersensitivity</p></td></tr><tr><td style="vertical-align:top"><p><em>Metabolism and nutrition disorders</em></p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Hypomagnesaemia</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><em>Nervous system disorders</em></p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Paralysis<sup>a</sup></p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Tremor<sup>a</sup>, paresthesia<sup>a</sup>, headache, balance disorder<sup>a</sup></p></td></tr><tr><td style="vertical-align:top"><p><em>Eye disorders</em></p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Blindness<sup>b</sup>, retinal infarction<sup>b</sup></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><em>Ear and labyrinth Disorders</em></p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Tinnitus<sup>a</sup>, hypoacusis<sup>a</sup></p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Deafness<sup>a</sup>, deafness neurosensory<sup>a</sup></p></td></tr><tr><td style="vertical-align:top"><p><em>Vascular disorders</em></p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Hypotension</p></td></tr><tr><td style="vertical-align:top"><p><em>Respiratory, thoracic and mediastinal disorders</em></p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Apnoea, bronchopasm</p></td></tr><tr><td style="vertical-align:top"><p><em>Gastrointestinal disorders</em></p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Nausea, vomiting</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><em>Skin and subcutaneous tissue disorders</em></p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Rash</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Pruritus, urticaria</p></td></tr><tr><td style="vertical-align:top"><p><em>Musculoskeletal, connective tissue and bone disorders</em></p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Arthralgia, muscle twitching <sup>a</sup></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><em>Renal and urinary disorders</em></p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Renal failure acute, nephropathy toxic, cells in urine<sup>a</sup></p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Oliguria<sup>a</sup>, blood creatinine increased<sup>a</sup>, albuminuria<sup>a</sup>, azotemia<sup>a</sup>, red blood cells urine<sup>a</sup>, white blood cells urine<sup>a</sup></p></td></tr><tr><td style="vertical-align:top"><p><em>General disorders and administration site conditions</em></p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Pyrexia</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>a </sup>See section 4.4.<br />bAmikacin is not formulated for intavitreal use. Blindness and retinal infarction have been reported following intravitreous administrations (injection into the eye) of amikacin.</p></td></tr></tbody></table><p>All aminoglycosides have the potential to induce ototoxicity, renal toxicity, and neuromuscular blockade. These toxicities occur more frequently in patients with renal impairment, in patients treated with other ototoxic or nephrotoxic drugs, and in patients treated for longer periods and/or with higher doses than recommended (see section 4.4)</p><p>Renal function changes are usually reversible when the drug is discontinued.</p><p>Toxic effects on the eighth cranial nerve can result in hearing loss, loss of balance, or both. Amikacin primarily affects auditory function. Cochlear damage includes high frequency deafness and usually occurs before clinical hearing loss can be detected by audiometric testing (see section 4.4).</p><p>Macular infarction sometimes leading to permanent loss of vision has been reported following intravitreous administration (injection into the eye) of amikacin.</p><p>When the recommended precautions and dosages are followed the incidence of toxic reactions, such as tinnitus, vertigo, and partial reversible deafness, skin rash, drug fever, headache, paraesthesia, nausea and vomiting is low. Urinary signs of renal irritation (albumin, casts, and red or white cells), azotaemia and oliguria have been reported although they are rare.</p><p><strong>Reporting of suspected adverse reactions</strong><br />Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><ul><li>Saudi Arabia</li></ul><p>The National Pharmacovigilance Centre (NPC)</p><p>SFDA Call Center: 19999<br />E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa/</p><ul><li>Other GCC States</li></ul><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In case of overdosage there is a general risk for nephro-, oto- and neurotoxic (neuromuscular blockage) reactions. Neuromuscular blockage with respiratory arrest needs appropriate treatment including application of ionic calcium (e.g. as gluconat or lactobionat in 10-20% solution) (see section 4.4). In the event of overdosage or toxic reaction, peritoneal dialysis or haemodialysis will aid in the removal of amikacin from the blood. Amikacin levels are also reduced during continuous arteriovenous hemofiltration. In the newborn infant, exchange transfusion may also be considered.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>ATC code: J01G B06</p><p>Amikacin is a semi-synthetic aminoglycoside antibiotic derived from Kanamycin A. It is active against a broad spectrum of Gram-negative organisms, including <em>pseudomonas</em>, <em>Escherichia coli</em> and some Gram-positive organisms, e.g. <em>Staphylococcus aureus</em>.</p><p>Aminoglycoside antibiotics are bactericidal in action. Although the exact mechanism of action has not been fully elucidated, the drugs appear to inhibit protein synthesis in susceptible bacteria by irreversibly binding to 30S ribosomal subunits.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Amikacin is rapidly absorbed after intramuscular injection. Peak plasma concentrations equivalent to about 20 mg/ml are achieved one hour after IM doses of 500 mg, reducing to about 2 &micro;g/ml 10 hours after injections.</p><p>Twenty per cent or less is bound to serum protein and serum concentrations remain in the bactericidal range for sensitive organisms for 10 to 12 hours.</p><p>Single doses of 500 mg administered as an intravenous infusion over a period of 30 minutes produce a mean peak serum concentration of 38 &micro;g/ml. Repeated infusions do not produce drug accumulation in adults with normal renal function. However, decreased renal function will lead to accumulation.</p><p>In adults with normal renal function the plasma elimination half-life of amikacin is usually 2-3 hours. 94-98% of a single IM or IV dose of amikacin is excreted unchanged by glomerular filtration within 24 hours. Urine concentrations of amikacin average 563 &micro;g/ml in the first 6 hours following a single 250 mg IM dose and 163 &micro;g/ml over 6-12 hours. Following a single 500 mg IM dose urine concentrations average 832 &micro;g/ml in adults with normal renal function.</p><p>Amikacin diffuses readily through extracellular fluids and is excreted in the urine unchanged, primarily by glomerular filtration<strong>.</strong> It has been found in pleural fluid, amniotic fluid and in the peritoneal cavity following parenteral administration.</p><p>Data from multiple daily dose trials show that spinal fluid levels in normal infants are approximately 10 to 20% of the serum concentrations and may reach 50% in meningitis.</p><p><strong>Intramuscular and intravenous administration</strong><br />In neonates and particularly in premature babies, the renal elimination of amikacin is reduced.</p><p>In a single study in newborns (1-6 days of post natal age) grouped according to birth weights (&lt;2000, 2000-3000 and &gt;3000g). Amikacin was administered intramuscularly and/or intravenously at a dose of 7.5 mg/kg. Clearance in neonates &gt;3000 g was 0.84 ml/min/kg and terminal half-life was about 7 hours. In this group, the initial volume of distribution and volume of distribution at steady state was 0.3 ml/kg and 0.5 mg/kg, respectively. In the groups with lower birth weight clearance/kg was lower and half-life longer. Repeated dosing every 12 hours in all the above groups did not demonstrate accumulation after 5 days.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There are no pre-clinical data of relevance to the prescriber which are additional to that already included in other sections of the SPC.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>-&nbsp;&nbsp;&nbsp; Sodium metabisulphite</p><p>-&nbsp;&nbsp;&nbsp; Trisodium citrate</p><p>-&nbsp;&nbsp;&nbsp; Sulfuric acid and/or sodium hydroxide</p><p>-&nbsp;&nbsp;&nbsp; Water for injection</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Amikacin is incompatible with some penicillins and cephalosporins, amphotericin chlorothiazide sodium, erythromycin gluceptate, heparin, nitrofurantoin sodium, phenytoin sodium, thiopentone sodium and warfarin sodium, and depending on the composition and strength of the vehicle, tetracyclines, vitamins of the B group with vitamin C, and potassium chloride.</p><p>At times, amikacin may be indicated as concurrent therapy with other antibacterial agents in mixed or superinfections. In such instances, amikacin should not be physically mixed with other antibacterial agents in syringes, infusion bottles or any other equipment. Each agent should be administered separately.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Before first opening: 24 months.

In use: 24 hours. 


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 25ᵒC.</p><p>Store in the original package.</p><p><em>In use storage precautions</em></p><p>Following dilution in 0.9% sodium chloride and 5% glucose solutions, chemical and physical in-use stability has been demonstrated for 24 hours at room temperature.</p><p>From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2-8&deg;C, unless dilution has taken place in controlled and validated aseptic conditions.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>2 ml amber glass ampoules with white one-point-cut (OPC).</p><p>Pack size: 6 Ampoules (2 ml).</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Single use only. Discard any unused contents.</p><p>The solution may darken from colourless to a pale yellow but this does not indicate a loss of potency.</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jazeera Pharmaceutical Industries
Al-Kharj Road 
P.O. Box 106229
Riyadh 11666, Saudi Arabia
Tel: + (966-11) 8107023, + (966-11) 2142472
Fax: + (966-11) 2078170
e-mail: SAPV@hikma.com

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                05 July 2023

            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>